BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.

Cancers (Basel) · 2021 · PMC8155874 · PMID 34063443

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Additionally, the subset of the BRAF mutated melanoma cohort of the cancer genome atlas (TCGA) harboring an EZH2 silent mutation, showed a highly significant enforced miR-129-5p expression compared to BRAF mutated melanoma patients with EZH2 wildtype ( Figure 3 E).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.